The following webcasts are scheduled. Participation is free, so please register to participate.
Please be aware that Webinars are hosted through GoToWebinar. If you are not already set up to view webinars through this service, please allow 5 minutes before the start of the webinar to establish access.
Date: July 8th, 2015 16: 00-16: 45 GMT (London time)
The CRISPR–Cas9 system can be used to disrupt specific genes leading to genetic knockouts. Thus, it has an advantage over traditional RNAi-based target validation assays in which incomplete knockdown can lead to ambiguous results. However, use of the CRISPR–Cas9 system has revealed that it can result in insertions and deletions (indels) that are in frame and transcription of the gene is maintained. Such cases enable cells which are dependent on the target gene to carry on proliferating, falsely indicating that the gene knockout can be tolerated. To overcome this, we have developed the Pathfinder Target Essentiality Assay, a medium-throughput assay to analyse CRISPR–Cas9-mediated gene editing on a clonal level to verify the zygosity and therefore the essentiality of the targeted gene. This webinar will discuss: - Problems with traditional target validation using shRNA methods - The use of CRISPR–Cas9 for target validation in a heterogeneous cell population - Development of the Pathfinder Target Essentiality Assay
Date: July 22nd, 2015 16: 00-17: 00 GMT (London time)
In this webinar we will focus on next generation sequencing and discuss: the effect of formalin treatment on molecular protocols and how it can be controlled, how to select the sequencing platform most appropriate for your sample, evaluation of whether structural variants are being detected by your assay and how Reference Standards can be used in each validation parameter.
Date: August 6th, 2015 15: 00-16: 00 GMT (London time)
The world of biomarker research has changed dramatically over the last 20 years with targeted therapy fundamentally changing drug development practices; there are not only new biomarkers but there are also complex biomarkers such as PD-L1. Due to this, the situation has moved to a matrix of therapeutics and companion diagnostics, rather than the direct 1:1 relationship of the past. With all this complexity it is essential to ensure the accuracy of biomarker analysis, however, manual assessments of complex biomarker expressions have been associated with significant inter- and intra-reader variability. There are ways of reducing certain types of errors associated with biomarker assessment and studies have shown that quantitative image analysis may be the solution. Therefore an essential part of blue sky thinking is toward the development of IHC Reference Standards and Quantitative Digital Pathology methods to deliver a strong scoring confidence. In response to these challenges, a blueprint proposal for companion diagnostic comparability was discussed at the FDA-AACR-ASCO Public workshop on March 24 2015. This blueprint proposal acts as a PD-L1 comparison study where a few highlights of the valuable efforts will be discussed including the goals and study design.
Paragraph explaining benefits of Biocair×